On the afternoon of May 13, Hao Jian, Huang Heqin, Executive Vice President &CEO Wang Mingjun, R&D Director Ma Yipeng, head of Production Qiao Dongjuan, Assistant Director of Shenzhen Inuo Transformation Research Institute Pan Yi and other groups visited Shenzhen Cell Valley. Our chairman Shi Yuanyuan, quality management director Zhang Xuefeng, production R & D director Feng Yaru, Chairman assistant Wei Zheng and R & D deputy minister Sun Rui warmly received, the two sides held a symposium.

 
Accompanied by Wei Zheng, assistant to the chairman of the board, Innoimmune visited the Shenzhen Cell Valley, which is about to be fully completed, and had a preliminary understanding of the founder team, corporate culture, and platform construction of Shenzhen Cell Valley. At the follow-up forum, Chairman Shi Yuanyuan introduced the company's one-stop service construction layout in viral vector production platform, cell production platform, IIT, IND auxiliary declaration platform and clinical research platform, and focused on the latest trends related to IND declaration, as well as Shenzhen Cell Valley has the only domestic industrial production of the underlying core technology of retroviral vector.

Director Hao Jian said that it was clear that the two sides should cooperate closely in the later development, and put forward expectations for the future cooperation between the two sides, and launched both safety and clinical effectiveness of TCRT anti-solid tumor drugs to benefit all beings; Huang Heqin said that the current priority is to transform science and technology into productivity, so that advanced technology from the laboratory to the market; Dr. Wang Mingjun introduced a number of pipelines in research, and said that Innoimmune will push its TCR-T products to IND as soon as possible, hoping to cooperate with Shenzhen Cell Valley for win-win cooperation, give play to their respective advantages, and jointly create the first domestic TCR-T cell products based on retroviral vectors to achieve a breakthrough from zero to one. This discussion exchange is of great significance for the cooperation between the two sides, the two sides have signed a strategic cooperation agreement, and have jointly declared the subject, the future in product development, clinical research and IND declaration and other aspects of comprehensive cooperation. The two sides make good use of their respective advantages, integrate resources, open up the whole industrial chain from research and development to production to approval, and promote the continuous innovation and rapid development of domestic cell products based on retroviral vectors!